Breaking Down the TRAILBLAZER-ALZ 2 Trial
Psychopharmacology and Psychiatry Updates
00:00
Intro
This chapter explores the Trailblazer ALS-2 trial's findings on denanumab, a monoclonal antibody intended for early symptomatic Alzheimer's disease. It emphasizes crucial aspects such as patient selection, safety concerns, and effective communication of treatment options for clinicians.
Play episode from 00:00
Transcript
